NEW YORK – CareDx reported after the close of the market on Tuesday that its second quarter revenues rose 33 percent year over year, thanks largely to a 41 percent increase in testing services revenues.
For the three months ended June 30, the molecular diagnostics company reported total revenues of $41.8 million, up from $31.5 million during the same period a year earlier, beating the average Wall Street estimate of $35.6 million.